SC
CTMX icon

Schulhoff & Co’s CytomX Therapeutics CTMX Stock Holding History

Schulhoff & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.24M Buy
477,550
+102,700
+27% +$521K 0.92% 30
2025
Q4 		$1.6M Buy
+374,850
New +$1.42M 0.67% 39

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schulhoff & Co's CTMX Position: Q1 2026 in Review

Schulhoff & Co increased its CytomX Therapeutics (CTMX) stake by 27% in Q1 2026, buying an estimated $521K and bringing the position to 477,550 shares worth $2.24M. The position accounts for 0.92% of the portfolio, ranked #30.

Schulhoff & Co first reported a position in CTMX in Q4 2025 and has held it in 2 quarters since. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Schulhoff & Co held 477,550 shares of CytomX Therapeutics worth $2.24M as of Q1 2026.
  • Schulhoff & Co bought 102,700 CytomX Therapeutics shares in Q1 2026, an estimated $521K.
  • CytomX Therapeutics made up 0.92% of Schulhoff & Co's portfolio in Q1 2026, its #30 holding.
  • Schulhoff & Co first reported a position in CytomX Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Schulhoff & Co's 13F filing for Q1 2026, filed 11 May 2026.